Imperative Care has announced the presentation of late-breaking, real-world data from a multicentre review of ischaemic stroke patients treated with Adapt 2.0—a next-generation approach to a direct aspiration first-pass technique (ADAPT) in mechanical thrombectomy. These findings were presented at the recent Society of Vascular and Interventional Neurology (SVIN) annual meeting (19–22 November 2025, Orlando, USA) by Maxim Mokin (University of South Florida, Tampa, USA).
According to the company, Adapt 2.0 combines 0.088-inch intracranial access, asymmetric aspiration and the continuous dual aspiration technique (CDAT) to provide fast and effective clot removal. Imperative’s Zoom stroke system is also claimed by the company to be the only mechanical thrombectomy system capable of performing a procedure using Adapt 2.0.
Within the data from this multicentre review of 124 consecutive ischaemic stroke patients treated with Adapt 2.0 using the Zoom system between April and September 2025, the most frequently reported occlusion site was the M1 segment of the middle cerebral artery (MCA; 48%), followed by the M2 segment (24%).
The review of clinically documented data found a 97% rate of final modified thrombolysis in cerebral infarction (mTICI) ≥2b and an 80% rate of final mTICI ≥2c across the 124 patients. In addition, the researchers observed a median procedure time of 17 minutes, with a median of one pass per procedure, as well as a 98% rate of full clot ingestion and capture in one or both Zoom Pods across a 113-patient cohort. According to Imperative, the outer Zoom 88 Pod captured clot in 35% of these 113 cases.
“In addition to the 17-minute median procedure time and the minimal number of passes per procedure, we saw a 98% rate of full clot ingestion in this cohort, meaning the entire clot was successfully captured in one or both Zoom Pods,” Mokin commented. “Clot was observed in the Zoom 88 Pod in 35% of all cases, which may have otherwise been lost without continuous dual aspiration on the inner and outer catheters. This underscores a key potential benefit of Adapt 2.0, providing physicians with greater control and confidence during stroke procedures by reducing the risk of clot loss and offering immediate visual feedback of clot capture. I look forward to future larger studies to further elucidate the clinical benefits of CDAT and Adapt 2.0 for stroke patients.”
A press release from Imperative states that Adapt 2.0 represents “the evolution of the original ADAPT technique”, which was initially studied and published in 2014, and “transformed” stroke thrombectomy by demonstrating the clinical value of direct aspiration as a frontline treatment method via “excellent” clinical and angiographic outcomes alongside efficiency and ease of use. Adapt 2.0 brings together the most advanced techniques and technologies into a streamlined approach for achieving faster, easier and more effective stroke cases, the company further claims.
